Low temperature process for preparing silicon oxide coated pharmaceuticals
A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more silicon oxide materials is provided. The method entails alternating exposing the particles to gaseous or vaporous SiCl 4 and gaseous or vaporous H 2 O at a reduced temperature and in the absence of a catalyst.
1. A method of preparing coated particles comprising an active pharmaceutical ingredient (API)-containing core enclosed by one or more silicon oxide layers, the method comprising:
(a1) loading particles comprising a hydrophobic API into a reactor;
(a2) applying gaseous SiCl 4 to the particles in the reactor;
(a3) performing one or more pump-purge cycles using inert gas;
(a4) applying gaseous H 2 O to the particles in the reactor; and
(a5) lowering the gaseous H 2 O pressure in the reactor to below 0.5 Torr,
(b) performing two or more reaction cycles, each reaction cycle consisting of steps (a2)-(a5), to increase the total thickness of the silicon oxide layer, thereby creating coated particles comprising an API-containing core, wherein reaction cycles take place between 25° C. and 50° C. in the absence of a catalyst, and there is no pump-purge cycle between the first and second reaction cycles.
2. The method of claim 1 , wherein there is no pump-purge cycle between the second and the third reaction cycles.
3. The method of claim 1 , wherein there is no pump-purge cycle between any of the first 10 reaction cycles.
4. The method of claim 1 , wherein there is no pump-purge cycle between any of the first 100 reaction cycles.
5. The method of claim 1 , wherein the particles are agitated prior to and/or during one or more of steps (a2) to (a5).
6. The method of claim 1 , wherein the particles are agitated prior to and/or during step (a1), step (a3), and/or step (a5).
7. The method of claim 1 , wherein a subset of gaseous SiCl 4 is pumped out prior to step (a3).
8. The method of claim 1 , wherein the silicon oxide layer has a thickness in a range of 0.1 nm to 50 nm.
9. The method of claim 1 , wherein the particles are not removed from the reactor between the reaction cycles.
10. The method of claim 1 , wherein the particles are not removed from the reactor during step until the silicon oxide layer is complete.
11. The method of claim 1 , wherein the API-containing core comprises one or more pharmaceutically acceptable excipients.
12. The method of claim 1 , wherein the particles in step (a1) have a median particle size, on a volume average basis between 0.1 μm and 20 μm.
13. The method of claim 1 , wherein the particles in step (a1) have a median particle size, on a volume average basis between 0.1 μm and 5 μm.
14. The method of claim 1 , wherein the particles in step (a1) have a median particle size, on a volume average basis between 0.1 μm and 1000 μm.
15. The method of claim 1 , wherein the API-containing core comprises the hydrophobic API and a second API.
16. The method of claim 1 , wherein the API-containing core consists of the hydrophobic API.
17. The method of claim 1 , wherein the API-containing core consists of the hydrophobic API and a second API.
18. The method of claim 1 , wherein the API-containing core comprises the hydrophobic API, a second API and one or more pharmaceutically acceptable excipients.
19. The method of claim 1 , wherein the API-containing core consists of the hydrophobic API and one or more pharmaceutically acceptable excipients.
20. The method of claim 1 , wherein the API-containing core consists of the hydrophobic API, a second API and one or more pharmaceutically acceptable excipients.
21. The method of claim 1 , wherein the API-containing core comprises the hydrophobic API and step (a1) further comprises one or both of (1) loading particles comprising a second API into the reactor (second particles) and (2) loading particles comprising one more excipients into the reactor (excipient particles).
22. The method of claim 1 , further comprising admixing the coated particles with a pharmaceutically acceptable diluent or carrier.
23. The method of claim 1 , further comprising processing the coated particles to form a tablet or capsule.
24. The method of claim 1 , further comprising admixing the coated particles with a pharmaceutically acceptable diluent or carrier to form a mixture and processing the mixture to form a table or capsule.
25. The method of claim 1 , wherein each pump-purge cycle comprises flowing an inert gas into the reactor to reach a pressure of at least 1 Torr and after a delay time evacuating the reactor to reduce the pressure of the inert gas to below 1 Torr.
26. The method of claim 1 , wherein the gaseous SiCl 4 is pumped into the reactor to reach a pressure of 2 to 200 Torr during step (a2).
27. The method of claim 1 , wherein step (a3) is the only pump-purge step.
28. The method of claim 1 , wherein the gaseous H 2 O is pumped into the reactor to reach a pressure of 2 to 20 Torr and is allowed to react with SiCl 4 in the reactor for 1-30 minutes during step (a4).
29. The method of claim 1 , wherein there is one or more pump-purge cycles between the second and each subsequent cycles.
30. The method of claim 1 , wherein there is one or more pump-purge cycles between the third and each subsequent cycles.
31. The method of claim 1 , wherein there is one or more pump-purge cycles between the 10th and each subsequent cycles.
32. The method of claim 1 , wherein there is one or more pump-purge cycles between the 100th and each subsequent cycles.